The Living Guidelines: UA/NSTEMI Recommendations for Anti Ischemic Therapy Suggest Revisions to the CLASS IIb Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Instructions on How to Edit the Guidelines:
 * Log in
 * Click on "Edit"
 * Type in changes to guidelines
 * Click "Save page" at the bottom of the page

Class IIb Guidelines

 * 1) The use of extended-release forms of non dihydropyridine calcium antagonists instead of a beta blocker may be considered in patients with UA / NSTEMI. (Level of Evidence: B)
 * 2) Immediate-release dihydropyridine calcium antagonists in the presence of adequate beta blockade may be considered in patients with UA / NSTEMI with ongoing ischemic symptoms or hypertension. (Level of Evidence: B)